脾多肽联合重组人粒细胞集落刺激因子在化疗后患者白细胞减少症中的应用效果及对患者免疫功能的影响

Application effect of spleen polypeptide combined with recombinant human granulocyte colony stimulating factor in patients with leukopenia after chemotherapy and its influence on immune function

目的探究脾多肽联合重组人粒细胞集落刺激因子(rhG-CSF)在化疗后患者白细胞减少症中的应用效果及对患者免疫功能的影响。方法纳入120例化疗后白细胞减少症患者,根据治疗方法的不同将其分为对照组和脾多肽组,各60例。对照组使用rhG-CSF进行治疗,脾多肽组在对照组基础上使用脾多肽治疗。比较两组的临床疗效疗、免疫功能指标(CD3^(+)、CD4^(+)/CD8^(+)、NK细胞)、临床指标(化疗延迟率、化疗延长时间、感染发生率、rhG-CSF用药量)、不良反应发生情况。结果脾多肽组的治疗总有效率明显高于对照组(P<0.05)。治疗后,脾多肽组的CD3^(+)、CD4^(+)/CD8^(+)、NK细胞水平均明显高于对照组(P<0.05)。脾多肽组的化疗延迟率、化疗延迟时间、感染发生率以及rhG-CSF用药量均明显优于对照组(P<0.05)。治疗后,两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论脾多肽联合rhG-CSF治疗化疗后患者白细胞减少症的效果确切,可促进患者免疫功能改善,减少化疗延迟,降低感染风险,且安全性好,值得推广。

Objective To explore the application effect of spleen polypeptide combined with recombinant human granulocyte colony stimulating factor(rhG-CSF)in patients with leukopenia after chemotherapy and its influencce on immune function.Methods A total of 120 patients with leukopenia after chemotherapy were enrolled.According to the different treatment methods,the patients were divided into control group and spleen polypeptide group,with 60 cases in each group.The control group was treated with rhG-CSF,and the spleen polypeptide group was treated with spleen polypeptide on the basis of the control group.The clinical efficacy,immune function indexes(CD3^(+),CD4^(+)/CD8^(+),NK cells),clinical indexes(chemotherapy delay rate,chemotherapy extension time,infection rate,rhG-CSF dosage)and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the spleen polypeptide group was significantly higher than that in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+)/CD8^(+),and NK cells level in the spleen polypeptide group were significantly higher than those in the control group(P<0.05).The delay rate of chemotherapy,the delay time of chemotherapy,the incidence of infection and the dosage of rhG-CSF in the spleen polypeptide group were significantly better than those in the control group(P<0.05).After treatment,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The spleen polypeptide combined with rhG-CSF has a definite effect in the treatment of patients with leukopenia after chemotherapy.It can improve patients'immune function,reduce chemotherapy delay and the risk of infection,and has good safety,which is worthy of promotion.